Myles Minter

Stock Analyst at William Blair

(1.96)
# 2,880
Out of 5,152 analysts
25
Total ratings
47.37%
Success rate
3.47%
Average return

Stocks Rated by Myles Minter

Korro Bio
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $10.95
Upside: -
Neumora Therapeutics
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $3.00
Upside: -
Biohaven
Nov 5, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $10.31
Upside: -
Alector
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.00
Upside: -
Dianthus Therapeutics
Jul 2, 2025
Initiates: Outperform
Price Target: n/a
Current: $61.43
Upside: -
Immunic
Mar 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.11
Upside: -
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.59
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $728.11
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $7.25
Upside: +879.31%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $53.83
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $460.82
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $310.58
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $5.22
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $320.51
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $75.16
Upside: -
Initiates: Outperform
Price Target: $116
Current: $129.64
Upside: -10.52%